Protocol
Running a tissue-repair protocol
What the record holds about the schedule for the classic repair stack: the interval, the half-life, and what the half-lives on file imply about it.
Last updated
4 of 7 hold a half-life measurement. A curve needs that and a schedule, which is why 4 lines are drawn below and 3 members appear in the table with no line at all.
Every half-life on file in this group was measured intravenously, and every one of these compounds is administered subcutaneously. That does not make the numbers useless — it makes them a lower bound, and the section below the charts says why in full. The other thing to read off the table is that nothing here accumulates: at the intervals on file, each dose has cleared before the next arrives.
The schedule on file
Read the last column first. Four kinds of thing get printed as a dose in this category and they are not the same kind of fact: an approved label, a trial protocol, a figure the community circulates, and arithmetic done on an animal study. What each chip means.
| Compound | Schedule on file | Half-life | Accumulation | Where the schedule comes from |
|---|---|---|---|---|
| TB-500curve | twice a week2-4 mg 2x/week | 1.3 h30 min to 2.1 hhuman, IV | noneeach dose has cleared before the next arrives | circulated |
| Thymosin alpha-1curve | daily1.6 mg daily | 2 hhuman, SC | noneeach dose has cleared before the next arrives | labelThymalfasin is licensed in around thirty countries and 1.6 mg twice weekly is its labelled schedule. No label for it is on file in this corpus. |
| ARA-290curve | daily4 mg daily | 2 minmice, route not stated | noneeach dose has cleared before the next arrives | trial |
| BPC-157curve | twice daily250-500 mcg daily | 15 minrat, IV | noneeach dose has cleared before the next arrives | circulated |
| Collagen Peptidesschedule only | daily2.5 - 15 g/day | not on file | —needs a half-life and an interval from the same record | trialOral doses of a few grams a day, from published trials. |
| KPVschedule only | daily200-500 mcg daily | not on file | —needs a half-life and an interval from the same record | circulated |
| GHK-Cuschedule only | twice daily1-2.5 mg 3x/week | not on file | —needs a half-life and an interval from the same record | circulated |
What the schedule does over time
Each line is one compound's amount in the body as a percentage of its own peak, from the first dose onwards. Compounds share a chart only when they share a dosing interval, because that is the only comparison the shape supports. Nothing here builds between doses; the multiplier is in the table above.
- TB-500 half-life 1.3 h, no accumulation
- Thymosin alpha-1 half-life 2 h, no accumulation
- ARA-290 half-life 2 min, no accumulation
- BPC-157 half-life 15 min, no accumulation the record says 7 to 14 times a week; the fastest is drawn
What the curves do not model
The half-life was measured by a different route than the one it is given by. TB-500, BPC-157 have intravenous half-lives on file and are not administered that way. That does not make the number useless — it makes it a lower bound. Absorption from the injection site keeps supplying the blood after an intravenous bolus would have cleared, so the real curve is flatter and lasts longer than the one drawn here. It is never shorter.
2 half-lives were measured in an animal. ARA-290 (mice), BPC-157 (rat). Small mammals clear peptides faster than people do, so those curves are the fastest plausible shape rather than the expected one. The species is on every row above and on the compound's own record.
The rise is not modelled. No absorption rate constant is on file for anything here, so every dose appears at full height the instant it is given. A real subcutaneous injection takes hours to peak. The decay is measured; the vertical line at each dose is a placeholder for a shape there is nothing to draw.
The axis is percent of each compound's own peak, and it is not a blood level. No volume of distribution is on file for anything on this page, so no curve here can carry a concentration. Two lines both at 50% are two compounds each at half of their own maximum — not two equal amounts of anything, and not a comparison of potency.
Combining within this class
Only the pairings somebody wrote a rule for are listed. A pairing that is absent is absent from our records, which is a statement about the records and not about safety. The full grid, including every pairing with nothing on record, is in the stack checker.
BPC-157 with TB-500no conflict on record
The most commonly reported repair pairing: different mechanisms (BPC-157 is gut-derived and angiogenesis-modulating; TB-500 is an actin-binding fragment supporting cell migration). No interaction is on record; the pairing's popularity is community practice, not trial evidence.
curated pair — complementary mechanisms, no interaction on record.
What the evidence says, separately
This page is about the schedule. It says nothing about whether any of it works — that is graded row by row against a named condition, and it lives on the goal pages, each of which opens with how many compounds were checked before it says which earned a row.
What this page does not say
It reports the schedules on file and what the measured half-lives imply about them. It does not recommend a compound, a dose, an interval or a combination, and a schedule appearing here is a record that somebody publishes it rather than a reason to run it. Three of the four source classes are not approvals of anything.
Lay this out as a week
The planner takes a list of compounds and turns it into administration days, with the vial maths and the same-syringe question answered per pairing.
- Open 6 compounds in the protocol builder — a week of administration days, built from the schedules above
- Check the same list in the stack checker — nine dimensions across every pairing, including the ones with nothing on record